Amgen’s Krystexxa lowers blood pressure in chronic gout trial

Amgen has reported findings from the MIRROR clinical trial where its Krystexxa (pegloticase) therapy reduced blood pressure in chronic gout patients.

The controlled, randomised trial enrolled 152 adult subjects with chronic gout refractory to oral urate-lowering therapy, irrespective of chronic kidney disease (CKD) status.